Comparative Pharmacology
Head-to-head clinical analysis: DANTROLENE SODIUM versus LIORESAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DANTROLENE SODIUM versus LIORESAL.
DANTROLENE SODIUM vs LIORESAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dantrolene sodium dissociates the excitation-contraction coupling in skeletal muscle by inhibiting calcium release from the sarcoplasmic reticulum via ryanodine receptor blockade.
GABA-B receptor agonist; inhibits monosynaptic and polysynaptic reflexes at the spinal cord level by reducing excitatory neurotransmitter release.
25 mg orally once daily for 7 days; then 25 mg three times daily for 7 days; then 50 mg three times daily for 7 days; then 100 mg three times daily. Maximum daily dose: 400 mg. For malignant hyperthermia: 1 mg/kg intravenously, may repeat up to cumulative dose of 10 mg/kg.
Oral: Initial 5 mg 3 times daily, increase by 5 mg per dose every 3 days to a maximum of 80 mg/day (20 mg 4 times daily). Intrathecal: Test dose 50-100 mcg; maintenance infusion 300-800 mcg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 8-10 hours in adults; may be prolonged to 12-15 hours in elderly or patients with hepatic impairment. Steady-state achieved in 3-4 days.
Terminal elimination half-life: 2.5-4 hours. Clinically, accumulation occurs in renal impairment, requiring dose adjustment.
Primarily hepatic metabolism; approximately 25% excreted in urine as metabolites, 45-50% in feces via bile; less than 1% unchanged in urine.
Renal: approximately 70-80% of the dose as unchanged drug and metabolites (primarily glucuronide conjugate); minor biliary/fecal elimination (<5%).
Category A/B
Category C
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant